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Is There an Immune Deficit in 
Whipple' s Disease? 
WILLIAM O. DOBBINS III, MD 
There is controversy as to the role of  immune deficiency, if any, in Whipple' s disease. This 
report summar&es published data in regard to immune function in this disease. Thirty-two 
publications during the past ten years offer varying amounts of  immunological data in 61 
patients--50 males, 6females, and 5 patients in whom the sex was not reported. There is 
no evidence for humoral immune deficiency in these patients. Secretory immunoglobulins 
are within normal limits. Intestinal mucosal plasma cells are decreased before treatment, 
but are normal after treatment. There are no abnormal deposits of  complement or immu- 
noglobulins within the intestinal mucosa. There is no evidence for autoantibody produc- 
tion. These patients invariably have lymphocytopenia prior to treatment and have a de- 
creased percentage o fT  cells both before and after treatment. There is decreased respon- 
siveness of  lymphocytes to the mitogens PHA and Con A, before and after treatment. The 
cutaneous response to antigens is clearly diminished before treatment, improves some- 
what after treatment, but is still significantly less than that seen in normal controls. There 
may be an increased association with HLA B27, which suggests that an abnormality in the 
cellular immune system promotes susceptibility to the Whipple bacillus. 
Whipple's disease is a systemic illness, largely re- 
ported from North America and continental Europe 
in which the great majority of the patients are 
middle-aged, white males. The major histological 
involvement is that of macrophage infiltration of the 
lamina propria of the small intestine and of its lym- 
phatic drainage. The presence of periodic acid- 
Schiff-positive macrophages has also been shown in 
most organ systems. The consistent presence of ba- 
cilli in the small intestine, lymph nodes, and other 
tissues of these patients prior to treatment has been 
repeatedly confirmed. The structural characteristics 
of the organisms in the untreated patient, their ab- 
sence after antibiotic therapy, and the uniformly 
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good clinical results with antibiotics leads one in- 
escapably to regard Whipple' s disease as a bacterial 
disease (1). That this apparent bacterial organism 
has not been cultured nor the disease reproduced in 
laboratory animals represents a major challenge. 
The necessity for successful culture of the bacterial 
organism is becoming  increasingly apparent .  
Whipple's disease in the absence of apparent in- 
testinal involvement has been identified (2-5). 
Thus, one can no longer rely entirely upon intestinal 
biopsy in order to make a diagnosis of this disease. 
Recent reports of Whipple's disease presenting as a 
central nervous system illness in the absence of in- 
testinal symptoms provides increasing impetus to 
culture the apparent etiologic organism, hopefully 
permitting development of a serological assay for 
the diagnosis of this disease (6, 7).  
HISTORICAL ASPECTS 
Patients with Whipple's disease are not unusually 
susceptible to ordinary viral and bacterial infec. 
tions. However, there may be an unusual host sus- 
ceptibility to the Whipple organism. The marked 
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TABLE 1. SERUM IMMUNOGLOBULINS (MG/ML)* 
Before After 
A G M A G M 
Barbier (16) 7.80 6.80 0.43 5.40 
Berens(17) 3.40 14.75 0.15 
Bloch (19) 2.20 8.50 0.50 
Buchholz (20) 2.22 
Cerf(10) 10.40 10.40 3.00 
2.10 7.50 0.50 
10.00 12.60 0.80 
5.00 15.00 0.60 
Clarity (39) 7.70 10.00 3.90 3.00 
Comet (24) 1.94 5.50 0.50 
Douglas (25) 8.00 1.50 1.45 
Groll (11) 15.00 18.50 1.20 5.90 
Haeney (27) 3.58 15.20 0.48 1.90 
Kirkpatrick (12) 3.10 14.50 0.43 
LeBodic (30) 9.50 15.00 1.60 3.24 
4.60 13.00 0.80 1.40 
2.40 6.89 0.15 
Lukacs (31) 3.00 12.00 0.80 
Maas (32) 3.10 9.00 0.32 
Myre (34) 3.90 
Pastor (35) 0.56 5.80 0.70 0.64 
Total 103.38 202.44 18.31 26.60 83.93 18.76 
Mean 5.44 10.65 0.96 3.07 9.33 2.08 
SD +3.82 +4.37 --+0.97 --+1.77 -+5.27 -+1.73 
*Results of serum immunoglobulins (mg/ml) in patients with 
Whipple's disease as reported by various authors. The refer- 
ence is in parentheses. The data are tabulated in relation to 
treatment, either before or after. When multiple serum immu- 
noglobu!in analyses were done after treatment, only the last 
reported result is recorded above. 
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terial in his own tissues (12). In 1979, Keren report- 
ed extensive immunological studies in three pa- 
tients with Whipple's disease and found minimal 
evidence for cell-mediated deficiency (13). Feurle 
10.50 0 .50  tested the cellular immune system in nine patients 
with Whipple's disease and found evidence (normal 
12.10 0 .90  mitogenic response of lymphocytes to phytohe- 
magglutinin and pokeweed mitogen but decreased 
response to concanavalin) suggesting a defect of a 
subclass ofT-cells, a defect that was more severe in 
6.00 2 .6o  patients with active disease than in treated patients 
(14). 
10.00 3.oo The major challenge today is still to successfully 
7.20 1.42 culture the apparent etiologic organism. The second 
14.13 1.35 challenge is to define the role of immune deficiency, 
4.oo 5.8o if any, in these patients. A summary of current pub- 
lished data in regard to immune funct ion in 
Whipple's disease should be helpful in deciding 
18.50 0 .26  whether there is consistent evidence for immune 
1.50 2.93 deficiency in these patients and, if so, in providing 
direction for future studies in order to further clarify 
the immune status of these patients. Thirty-two 
publications during the past ten years offer varying 
amounts of immunological data in 61 patients--50 
males, 6 females, and 5 patients in whom the sex 
was not reported (3, 9-39). Most of these reports 
have appeared since the publication of our compre- 
hensive review of this disease (1). 
paucity of plasma cells within the intestinal lamina 
propria of untreated patients with this disease was 
first emphasized in 1967 (8). In 1968, Maxwell 
showed decreased lymphocyte responsiveness to 
phytohemagglutinin (PHA) in a patient following 
treatment (9). This observation suggested that these 
patients had a cell-mediated immune (CMI) deficit 
rather than a humoral immune deficit. In 1970, it 
was suggested independently by two groups that the 
presumed cell-mediated immune defect might relate 
to defective macrophage processing of the bacterial 
antigen (1, 10). This observation was based upon 
morphological data, and no functional studies were 
done to support the morphological observations. In 
1972, Groll proposed that a disorder of cellular im- 
mune function permitted the rod-shaped organism 
to gain a foothold in tissues and proliferate until a 
state of specific immunological tolerance developed 
(11). In 1978, Kirkpatrick found no evidence for 
CMI deficiency in a single patient but further sup- 
ported the possibility of immunological tolerance 
when he noted the absence of antibody in the pa- 
tient's convalescent serum to the PAS-positive ma- 
HUMORAL IMMUNITY 
Table 1 lists the patient immunoglobulin levels 
derived from reports. Using mean values -+ 1 stan- 
dard deviation from the laboratory of Dr. T.A. 
Waldmann of the NIC, NIH (IgG 12.1 - 2.6, IgA 
2.6 + 1.1, and IgM 1.4 -+ 0.6 mg/ml), it can be seen 
that IgG and IgM are normal before treatment, 
while IgA is high. Immunoglobulin levels were nor- 
real after treatment. Immunoglobulin levels were 
said to be "normal" in four patients studied before 
and in nine patients studied after treatment (9, 15, 
22, 29, 33). There is one report of Whipple's disease 
in a patient with common variable hypogammaglob- 
ulinemia (23). 
Normal levels of secretory IgA were found in sa- 
liva and in intestinal secretions in all nine patients 
tested for this secretory immunoglobulin (10, 11, 25, 
30). Normal levels of secretory component bound 
to IgA were found in parotid and intestinal secre- 
tions of the single patient tested for this, and free 
secretory component was found to be present in the 
intestinal secretions of the same patient (11). Immu- 
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nofluorescent studies utilizing fluorescent-labeled 
antibodies to IgA, IgG, and IgM to quantitate 
plasma cells within the intestinal lamina propria are 
reasonably consistent (9-11, 16, 20, 27, 28, 30, 37, 
38). Before treatment, intestinal mucosal plasma 
cells were decreased in 12 patients, normal in 5, and 
increased in 1. After treatment, intestinal mucosal 
plasma cells were reported to be decreased in only 4 
patients and to be normal in 7 patients. No consist- 
ent abnormalities in the relative proportions of the 3 
classes of plasma cells were noted. Faint deposits of  
complement (C3) below the epithelial basement 
membrane were noted by Buchholz (20), and faint 
deposits of IgG in the same location were reported 
by Haeney (27). Serum complement levels (C3 in all 
reports, C4 in three) were found to be normal in 5 
patients prior to treatment and in 10 other patients 
studied after treatment (20, 21, 27, 31, 33, 38, 39). 
Very slightly decreased C3 levels were noted in a 
single pat ient  af ter  t rea tment ,  and immuno- 
fluorescent staining of the intestinal biopsy of this 
patient showed faint deposits of C3 below the epi- 
thelial basement membrane (20). 
Serum antibodies were detected in normal titers 
to streptococci, Salmonella species, E. coli, Hemo- 
philus influenza type B, pneumococci, Vibrio chol- 
era, diphtheria, and tetanus when tested in a small 
number of patients (9, 11, 20, 30, 31). A single Pa- 
tient had absence of serum hepatitis B surface anti- 
gen (HBsAg) prior to treatment, but was found to 
have presence of H B ~ g  in blood, serum, saliva, 
and intestinal secretions after treatment, at which 
time the liver biopsy showed evidence of subsiding 
hepatitis (27). Rheumatoid factor, antinuclear anti- 
body (ANA), antimitochondrial antibody (AMA), 
anti-smooth-muscle antibody were foufid to be ab- 
sent (9, 18, 20 ,30,  31, 33, 36). Clancy found low 
titers (1 : 10) of anti-smooth-muscle antibody and of 
AMA in one patient before treatment. ANA was ab- 
sent in this patient, and all assays for autoantibodies 
were negative after treatment (39). LE cells have 
not been detected (20, 36). Antibodies to thyroid 
microsomes, thyroglobulin, parietal cells, and sali- 
vary tissues were absent (9, 31). Isohemagglutinin 
titers were normal (20). Serological assays for in- 
fluenza, coxsackie, and psittacosis viruses were re- 
ported to be negative in one patient (18). 
CELLULAR IMMUNITY 
Lymphocytopenia has almost invariably been 
present prior to treatment, with the lymphocyte lev- 
els returning to low normal levels after treatment. 
The mean of T lymph0cytes was 41% in 11 patients 
prior to treatment and the mean was 45% in i2 pa- 
tients after treatment (12-14, 16, 27, 30, 39). A rea- 
sonable normal mean for human peripheral T lym- 
phocytes is 60% with a standard deviation of 10 (13, 
14). Thus, the percentage of T lymphocytes, both 
before and after treatment, was consistently low. 
The percentage of B lymphocytes was normal be- 
fore and after treatment in five patients (12, 16, 27, 
28, 39). The mitogenic response of peripheral blood 
mononuclear (PBM) cells (lymphocyte response) to 
phytohemagglutinin (PHA) was a mean of 69% of 
normal in 15 patients studied before treatment (10- 
12, 14, 16, 27, 30, 31, 38, 39) and was a mean of 65% 
of normal after treatment in 25 individuals (9, 11, 
13, 14, 16, 27, 30, 33, 35, 38). 
It should be kept in mind that this testing was 
done in a variety of laboratories, utilizing various 
amounts of the mitogen, generally ranging from 2.0 
to 10.0 /xg/ml, and testing the mitogenic response 
usually after 3 days but sometimes after 4 and 5 
days. Nevertheless, all of the responses were ex- 
pressed as percent of normal mean for each labora- 
tory. The data suggest a consistently diminished re- 
sponsiveness of lymphocytes, both before and after 
treatment, to the mitogen PHA. 
Other lectins, concanavalin A (Con A), and poke- 
weed mitogen (PWM) were tested in a very few pa- 
tients. Similar to the findings with PHA, there was 
generally a decreased responsiveness of lympho- 
cYtes to these mitogens (12-14, 27, 30, 38). Three 
reports bear cloSer scrutiny. Martin found a signifi- 
cantly decreased response (P > 0.001) of PBM to 
PHA in 7 patients with treated Whipple's disease 
and in 1 patient studied during treatment, when 
compared with the response in 11 healthy adults 
(33). Keren emphasized that he was able to find 
minimal evidence for ceil-mediated immune defi- 
ciency in the three treated patients that he studied. 
His data show decreased responsiveness of lym- 
phocytes in these three patients to PWM, PHA, and 
Con A. If one merely compares the means of the 
results of 36 analyses in these 3 patients to the mean 
normals reported from his laboratory, 31 of the 36 
responses were decreased, i f  one further analyzes 
this data in relation to a difference of one standard 
deviation, then 27 of the 36 responses were below 
the normal means for his laboratory (13). Feurle re- 
ported data on 9 patients, three untreated and six 
following treatment (14). Considering entire groups 
(treated and untreated together), only the response 
to Con A was significantly depressed (P < 0.02), 
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TABLE 2. CUTANEous RESPONSE TO ANTIGENS* 
Before After 
treatment treatment 
Tuberculin 5/21 7/26 
Candida 2/16 6/15 
Trichophyton 0/8 2/17 
Hist0plasmin 1/5 1/10 
Mumps 0/8 5/14 
SKSD 1/7 1/11 
DNCB 1/4 1/3 
Total 10/69 13% 23/96 24% 
*Tabulation of reported skin test responses in patients with 
Whipple's disease in relation to treatment. The numerator rep- 
resents number of positive responses while the denominator 
represents the total number of patients tested. 
while Con A stimulated the patients in remission 
significantly less (P < 0.04) than the controls. He 
pointed out that the differing responses to PHA and 
Con A may be due to differing action of the mito- 
gens on suppressor and helper T cells. He inter- 
preted these results to be compatible with evidence 
that there is a persistent defect of T lymphocytes in 
Whipple's disease and that this impairment resides 
in a subclass of  T lymphocytes (14). 
M o s t  of the reports cited give some information 
in regard to the cutaneous response to antigens. 
Thus, the data will not be referenced but are sum- 
marized in Table 2. The data in Table 2 suggest that 
there is a defect in cutaneous reactivity to several 
antigens both before and after treatment, but con- 
trol data in several studies are lacking. In two con- 
trolled studies the findings were as follows: Feurle 
assessed skin test antigen (trichophyton, Candida, 
tuberculin, SKSD) responses in 21 male inpatients 
with disease not associated with impaired delayed 
hypersensitivity, a group that was matched for age 
and sex with the 9 patients he studied. He found a 
positive response of 33/81 (41%) in this group of 
controls, no response in 3 untreated patients, and 
only 4 positive responses to 24 skin tests (17%) in 6 
treated patients in remission (14). Martin assessed 
c u t a n e o u s  hypersens i t iv i ty  in 7 pat ients  with 
treated Whipple's disease utilizing 23 different anti- 
gens and compared the results to those found in 138 
control patients (3). Delayed hypersensitivity reac- 
tions were significantly depressed, when compared 
to control, in all 7 patients tested and 5 of the pa- 
tients exhibited no delayed reactions to all 23 of the 
antigens. Skin graft rejection was tested in a single 
patient (11). A homograft applied before treatment 
was accepted for over 4 months and a second graft 
placed after 3 months of treatment was also rejected 
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slowly (11). Thus, there appears to be a significant 
degree of  cu taneous  anergy in pat ients  with 
Whipple's disease, both before and after treatment. 
HLA typing was done in 15 patients (3, 11, 12, 14, 
19, 21, unpublished). Six of the 15 (40%) patients 
were B27 positive. Only 10% of the general popu- 
lation is B27 posi t ive  (14). The associa t ion  of  
Whipple's disease with HLA B27 may be further 
evidence that an abnormality in the cellular immune 
system promotes susceptibility to the Whipple orga- 
nism. 
The histopathological response in Whipple's dis- 
ease is generally described as an infiltrative one in 
which macrophages are predominant. Sometimes 
the inflammatory reaction is granulomatous in na- 
ture (6, 15, 19, 22, 24, 25, 32, 36, 40) and in two 
patients has been described as "sarcoid-like" (15, 
36). A granulomatous response to injury, whether 
bacterial or otherwise, has been taken as an in- 
dication of alteration in cell-mediated immune func- 
tion. 
Phagocytic activity by PMN leukocytes and by 
macrophages, and lymphokine production by lym- 
phocytes is an area that has been generally neglect- 
ed in studies of Whipple's disease. Lukacs found a 
slightly decreased index of PMN and macrophage 
phagocytosis in one patient studied before treat- 
ment (31). Intracellular killing of fungi by PMN leu- 
koCytes was also shown to be 56% of normal (31). 
No studies were done after treatment. Tytgat stud- 
ied one patient after treatment and showed that 
PMN chemotaxis was minimally diminished, that 
PMN phagocytosis of Staphylococcus aureus was 
within normal limits, and that PMN killing of the 
same organism was slightly diminished (38). Barbier 
showed low secretion of migration inhibitory factor 
(MIF) by lymphocytes in response to SKSD in one 
patient before treatment, but showed a normal MIF 
response one year after treatment (16). Decreased 
macrophage adherence to glass was reported in one 
patient with Whipple's disease (22). Clancy demon- 
s t r a t ed  normal neutrophi l  funct ion and normal  
serum opsonizing capacity in a single patient (39). 
CONCLUDING REMARKS 
The evidence supporting immunodeficiency ob- 
tained in patients prior to treatment must be dis- 
counted. Severe malnutrition and partial obstruc- 
tion of intestinal mucosal lymphatics could account 
for all of the observed changes in immune function 
in the untreated patient. Further, transient anergy is 
the normal immune response to some infections 
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(41). There may be a subtle defect of cell-mediated 
immune funct ion in the t reated patient .  The 
Whipple bacillus may be an intracellular pathogen, 
similar to Listeria monocytogenes, salmanellae, 
and brucellae. Unlike pyogenic bacteria, which af- 
ter phagocytosis are rapidly digested by the macro- 
phage, intracellular pathogens survive inside the 
macrophage, unless the macrophage is activated. 
The immune response to intracellular pathogens re- 
quires interact ion be tween T cells and macro- 
phages, resulting in production of lymphocyte me- 
diators requiring a two-stage interaction (42). Ex- 
ploration of this aspect of macrophage-lymphocyte 
interaction may be a fruitful area for investigation in 
Whipple's disease. Production of lymphokines, es- 
pecially macrophage activating factor, should be 
explored. If there is indeed an abnormality in cellu- 
lar immune function in these patients, it may reside 
in a subset of T cells as pointed out by Feurle (14). 
The function of immunoregulatory T cells should be 
studied (43), and the role of T cell regulation of the 
immune response as it relates to the mucosal im- 
mune system should be explored (44). 
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